Orexigen Therapeutics — Merger or Acquisition (March 2016)
43 slides from Orexigen Therapeutics's merger presentation, Mar 15, 2016
Slide 1: Orexigen announces acquisition of all U.S. Contrave rights
Orexigen announces acquisition of all U.S. Contrave® rights March 15th 2016 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements about Orexigen Therapeutics, Inc. and Contrave®. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “should,” “intends,” “potential,” “suggests,” “assuming,” “designed” and similar express
Slide 3: Indication and important safety information
Indicated for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid conditio
Slide 4: Acquisition of U.S. Contrave rights transformational for Orexigen
Acquisition of U.S. Contrave® (naltrexone HCl / bupropion HCl) rights transformational for Orexigen Orexigen acquires all U.S. rights to Contrave, pending HSR clearance Rare opportunity for non-competitive acquisition of most prescribed brand in a growing market at an ideal point in the product’s li
Slide 5: Valeant commercialization and distributorship agreement for Central and Eastern Europe
For investor purposes only – not for use in product promotion Valeant commercialization and distributorship agreement for Central and Eastern Europe Terms of the agreement Valeant to commercialize and distribute Mysimba® in 18 Central and Eastern European countries, and Turkey Mysimba already approv
Slide 6: Overview of Major Terms for the US Contrave Rights Acquisition from Takeda
Overview of Major Terms for the US Contrave Rights Acquisition from Takeda $60M paid to Takeda upon close of transaction and NDA transfer to Orexigen Transition plan Transition period 180 days or sooner, at Orexigen’s election Decision-making authority shifts to Orexigen Carefully constructed transi
Slide 7: Acquiring Contrave rights at this point in the product's lifecycle is a tremendous opportunity
Acquiring Contrave rights at this point in the product’s lifecycle is a tremendous opportunity Takeda’s heavy investment in the launch yielded a great starting point for Orexigen 100,000 HCP’s have been called on to date, 1.1 million details delivered Many well trained speakers delivered hundreds of
Slide 8: Summary of Post-Transition US Commercial Opportunity
Summary of Post-Transition US Commercial Opportunity
Slide 9: Commercial Summary: Orexigen's Post Transition Plans
Commercial Summary: Orexigen’s Post Transition Plans Over the next three years, sales and profitability goals can be achieved through three key commercial strategies: Launch an effective and efficient U.S. commercial organization for Contrave Achieve strong growth of Contrave by differentiating vs g
Slide 10: Product lifecycles follow predictable phases
Product lifecycles follow predictable phases Sales Time Launch Growth Maintain Maximize Profit
Slide 11: In certain cases, specialty organizations optimize the growth phase
In certain cases, specialty organizations optimize the growth phase Primary Care Sales Force Specialty Sales Force LAUNCH Phase GROWTH Phase SOV/reach & frequency Physician awareness Speaker Programs Managed care access Launch capabilities Lack of focus and limited ownership as other priorities are
Slide 12: High concentration of prescribers lends itself to a specialist sales force
The high concentration of prescribers in the anti-obesity market lends itself to a specialist sales force Source: IMS Prescriber Profiler; Date range for data is Jan 2015 – Dec 2015 Prescribers that make up 60% of the business by Rx Class HCP Counts
Slide 13: Targeting process starts with ~19,600 responsive targets
Targeting process starts with ~19,600 responsive targets Source: IMS Prescriber Profiler; Date range for data is Jan 2015 – Dec 2015 4,600 3,100 7,700 HCPs writing 60% of Contrave Rx (Deciles 5 – 10) 15,000 HCPs writing 60% of Phentermine Class Rx (Market Deciles 5 – 10) 11,900 Combines to ~19,600 p
Slide 14: Identifying the ~18,000 most promotion responsive and profitable targets
Identifying the ~18,000 most promotion responsive and profitable sales force targets 19,600 highest prescribers of Contrave & Obesity Rx ~2,000 ~5,000 ~2,000 19,600 top anti-obesity and Contrave prescribers 2. REMOVE 3. ADD Low promotion response and/or inaccessible targets (become MCM targets) Phys
Slide 15: ~18,000 targets responsible for 76% of Contrave and 56% of phentermine prescriptions
~18,000 targets responsible for 76% of Contrave and 56% of phentermine prescriptions ~18,000 Targets Degree of Influence Promotion Response Adoption Sequence 200,000 Obesity Prescribers 55,000 Contrave Prescribers 1.2M+ details to 105,000 HCPs Prescribing Behavior 25,000 speaker program attendees So
Slide 16: Effective and Efficient US Commercial Organization
Effective and Efficient US Commercial Organization with ~90% customer facing roles Director, Comm. Ops Sr. Director, Global Comm. Eff Sr. Director, CA&I Manager, Sales Report & IC Manager, Training Manager, Field Comm & Logistics Sr. Director, US Marketing VP US Marketing Director, Consumer Marketin
Slide 17: Concentrations of targets define territories
Concentrations of targets define territories Smart Routing allows for efficient targeting of “next best opportunity” within territories 1 2 3 Physician Segment Annual Call Frequency A + 18 A – 12 B 8 Analytics drive targeting within territories Promotion Response sets optimal call frequencies Illust
Slide 18: Frequency and depth of HCP interactions to increase
Frequency and depth of HCP interactions to increase with ~18,000 physician targets Primary Care Sales Force Dedicated Specialty Sales Force 35% of 600K PDEs Product discussions shared with 2-3 other products in portfolio Single product discussions Estimated Capacity Product Discussions Time Spent on
Slide 19: Engagement strategy spans multiple channels
Note: 1. Speaker program and online sample offerings may overlap Targeted E-mail Speaker Programs1 Online Samples1 Digital Campaign Non-target Prescribers (~163,000) Primary Targets (~18,000) KOLs (~200) Account follow up as directed by field Coverage of vacancies Outbound calls & prospecting MCM pr
Slide 20: Commercial Summary: Differentiating vs generic amphetamines
Over the next three years, sales and profitability goals can be achieved through three key commercial strategies: Launch an effective and efficient U.S. commercial organization for Contrave Achieve strong growth of Contrave by differentiating vs generic amphetamines Improve G:N ratio through managed
Slide 21: US branded leadership a source of competitive advantage
TRx Market Share Contrave 41% Belviq 27% Qsymia 26% Saxenda 7% Source: IMS Health NPA Monthly Branded Anti-obesity Market US branded leadership a source of competitive advantage
Slide 22: Generic amphetamines present opportunity for growth
Source: 1. IMS Health Note: Orlistat and other medicines not included (c. 7% of market) Branded products include: Contrave, Qsymia, Belviq, and Saxenda Generic amphetamines present opportunity for growth Monthly TRx Other Branded Drugs1 Phentermine Anti-obesity Market
Slide 23: 56% of patients have tried phentermine previously
Rx for 1st Time Rx for 4thTime Rx for 3rd Time Rx for 2nd Time Q126. In the previous question, you indicated that you have prescribed phentermine to some of your overweight/obese patients in the past 3 months. What % of them fall within the following categories? The total must sum up to 100% Quantit
Slide 24: Physician receptivity to switching from phentermine
Q26. You indicate that you prescribe phentermine to your overweight and/or obese patients. Based on your experience, what % of those patients on phentermine eventually reach their weight loss goals? Q27. You mentioned that % of your phentermine patients reach their weight loss goals. For your patien
Slide 25: 64% of phentermine prescribers likely to prescribe Contrave
Source: HCP Quant Research Fielded Feb 2016 – HCP Survey An estimated 64% of phentermine prescribers would be likely to prescribe Contrave After reviewing Contrave’s product profile, self-identified phentermine prescribers were asked to describe their views on Contrave and likelihood of prescribing
Slide 26: Product attributes in the PIs may provide differentiation
Product attributes in the PIs may provide a key source of differentiation Contrave is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management Contrave has effects on two separate areas of the brain involved in the regulation of food intake (hyp
Slide 27: Physician awareness has reached threshold for activated consumers
Physician awareness has reached the threshold where activated consumers are likely to encounter a receptive physician Source: 1. Feb 2016, Qualtrics internet survey, HCP distribution: 51% PCP, 18% ENDO, 18% MLP, 13% OBGYN Q100. We would like you to think about prescription products to treat obesity.
Slide 28: Patient insight: two areas of brain regulate food intake
Patient insight: two separate areas of brain involved in the regulation of food intake Objective: encourage patients to ask their doctor about new Rx medicines that might be right for them hypothalamus (appetite regulatory center) mesolimbic dopamine circuit (reward system) 28
Slide 29: Media Plan: Ensure connectivity across patients and HCPs
Media Plan: Ensure connectivity across patients and HCPs There is an opportunity to activate the right patients and connect them with the right physicians via social media and geo-targeting Help Seeking (Physician) Help Seeking (Friends/Web) Not Help Seeking High Multiple Attempts Medium Considered
Slide 30: Commercial Summary: Managed care and pharmacy discount strategies
Over the next three years, sales and profitability goals can be achieved through three key commercial strategies: Launch an effective and efficient U.S. commercial organization for Contrave Achieve strong growth of Contrave by differentiating vs generic amphetamines Improve G:N ratio through managed
Slide 31: Evolving managed care contracting strategy
Evolving managed care contracting strategy will maximize access and drive profitable demand Two-phase approach to maximize enrollment and access within managed care Gain parity with other branded agents Focus on open access and typically Tier 3 coverage Leverage branded-leader status to strive for l
Slide 32: Profitability/Rx projected to improve across customer types
Profitability/Rx is projected to improved in aggregate across the portfolio of customer types Revenue Captured Discount Cash Pay Commercial Pay 4Q2015 2017 (proj.) 2018 (proj.) Cash Pay Commercial Pay With Savings Card Without Savings Card 69% 64% 60% 5% 7% 8% 11% 13% 17% 15% 16% 16% % Patient Mix b
Slide 33: Summary
Summary Over the next three years, sales and profitability goals can be achieved through three key commercial strategies: Launch an effective and efficient U.S. commercial organization for Contrave Achieve strong growth of Contrave by differentiating vs generic amphetamines Improve G:N ratio through
Slide 34: Financial implications and conclusions
Financial implications and conclusions
Slide 35: Financial implications
Financial implications Orexigen believes acquisition of Contrave maintains path to profitability by full year 2019 with overall potential long-term profitability magnified significantly To achieve 2019 profitability goals, Orexigen assumes: The overall anti-obesity market grows an average 5-10% thro
Slide 36: Acquisition of U.S. Contrave rights transformational for Orexigen
Acquisition of U.S. Contrave rights transformational for Orexigen Rare opportunity for non-competitive acquisition of most prescribed brand in a growing market at an ideal point in the product’s life cycle Acquisition of U.S. rights significantly magnifies overall potential profitability and creates
Slide 37: Additional slides
ts OREXIGEN Additional slides
Slide 38: Significant ex-US Sales Potential for Contrave / Mysimba
Country 2014 Sales (M) Peak Year Sales (Year) Mexico $140 $213 (2008) Brazil $120 $164 (2008) Russia $67 $84 (2012) Korea $58 $79 (2008) Australia $56 $58 (2012) MENA* $34 $40 (2010) Canada $14 $36 (2006) India $10 $15 (2010) China $.27 $.37 (2013) Europe $94 $508 (2007) Significant ex-US Sales Pote
Slide 39: Kwang Dong Distributorship Agreement
Kwang Dong Distributorship Agreement is example of Orexigen’s preferred ROW partnership strategy Terms of the agreement Kwang Dong is responsible for obtaining regulatory approval and for all commercialization activities and expenses Orexigen will supply Contrave® tablets to Kwang Dong for a $7 mill
Slide 40: Potential Commercialization Opportunities Outside the United States
Potential Contrave / Mysimba Commercialization Opportunities Outside the United States EU: Multiple parties conducting diligence under CDA for Italy, Spain/Portugal, UK, Austria Executed Commercialization and Distributorship Agreement with Valeant for 18 CEE countries + Turkey Australia/New Zealand:
Slide 41: Global Partnership Strategy
Global Partnership Strategy Rest of World: Seeking full partnership agreements (Kwang Dong is model) EU, MENA: Seeking co-marketing and distribution agreements
Slide 42: Orexigen Manufacturing and Supply Strategy
Orexigen Manufacturing and Supply Strategy Effective Lean & Efficient Flexible Experienced management World-class suppliers and manufacturers High quality and reliability Expertise in opiate manufacturing and Tri-layer CR manufacturing technology Network of 3rd Party suppliers/manufacturers/distribu
Slide 43: Broad and Growing Patent Estate
Broad and Growing Patent Estate 2034 2031 2032 2029 2027 2027/29 2024 2024/25 Binge Eating (methods) Major Depression (methods) Visceral Fat (methods) Titration (methods) Tri-layer tablet (methods & compositions) Insulin Sensitivity (methods & compositions) Weber / Cowley (methods & compositions) Pe
Orexigen Therapeutics — Merger or Acquisition (March 2016) on 6ix